Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Expression of mutant Sftpc in murine alveolar epithelia drives spontaneous lung fibrosis
Shin-Ichi Nureki, Yaniv Tomer, Alessandro Venosa, Jeremy Katzen, Scott J. Russo, Sarita Jamil, Matthew Barrett, Vivian Nguyen, Meghan Kopp, Surafel Mulugeta, Michael F. Beers
Shin-Ichi Nureki, Yaniv Tomer, Alessandro Venosa, Jeremy Katzen, Scott J. Russo, Sarita Jamil, Matthew Barrett, Vivian Nguyen, Meghan Kopp, Surafel Mulugeta, Michael F. Beers
View: Text | PDF
Research Article Pulmonology

Expression of mutant Sftpc in murine alveolar epithelia drives spontaneous lung fibrosis

  • Text
  • PDF
Abstract

Epithelial cell dysfunction is postulated as an important component in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Mutations in the surfactant protein C (SP-C) gene (SFTPC), an alveolar type II (AT2) cell–restricted protein, have been found in sporadic and familial IPF. To causally link these events, we developed a knockin mouse model capable of regulated expression of an IPF-associated isoleucine-to-threonine substitution at codon 73 (I73T) in Sftpc (SP-CI73T). Tamoxifen-treated SP-CI73T cohorts developed rapid increases in SftpcI73T mRNA and misprocessed proSP-CI73T protein accompanied by increased early mortality (days 7–14). This acute phase was marked by diffuse parenchymal lung injury, tissue infiltration by monocytes, polycellular alveolitis, and elevations in bronchoalveolar lavage and AT2 mRNA content of select inflammatory cytokines. Resolution of alveolitis (2–4 weeks), commensurate with a rise in TGF-β1, was followed by aberrant remodeling marked by collagen deposition, AT2 cell hyperplasia, α–smooth muscle actin–positive (α-SMA–positive) cells, and restrictive lung physiology. The translational relevance of the model was supported by detection of multiple IPF biomarkers previously reported in human cohorts. These data provide proof of principle that mutant SP-C expression in vivo causes spontaneous lung fibrosis, strengthening the role of AT2 cell dysfunction as a key upstream driver of IPF pathogenesis.

Authors

Shin-Ichi Nureki, Yaniv Tomer, Alessandro Venosa, Jeremy Katzen, Scott J. Russo, Sarita Jamil, Matthew Barrett, Vivian Nguyen, Meghan Kopp, Surafel Mulugeta, Michael F. Beers

×

Figure 3

Tamoxifen induction of SftpcI73T expression in IER-SP-CI73TFlp mice causes mortality and lung injury.

Options: View larger image (or click on image) Download as PowerPoint
Tamoxifen induction of SftpcI73T expression in IER-SP-CI73TFlp mice caus...
(A) IER-SP-CI73TFlp mice were generated by crossing a Rosa26-ER2-Flp-O (deleter) line (R26ERFLPo/FLPo) with SP-CI73T-Neo mice. (B) qRT-PCR analysis of Sftpc mRNA in IER-SP-CI73T/I73TFlp+/– (gray bars) or IER-SP-CI73T/I73TFlp–/– (white bars) mice at 3, 7, 14, and 42 days after tamoxifen (TAM). Normalized data are expressed as percent Sftpc WT (C57BL/6) mRNA standard. *P < 0.05 versus time point control by 2-tailed t test. (C) Top: Anti-HA Western blot of lung homogenates from double-heterozygous IER-SP-CI73T/WTFlp+/– mice 2 weeks after tamoxifen (200 mg/kg) or vehicle (oil) treatment showing upregulation of HA-proSP-CI73T isoforms (blue arrows). Bottom: Reprobing for α–proSP-C showing 22/21-kDa proSP-CWT (dotted rectangle) and 6-kDa proSP-C intermediate (black arrows), plus aberrant proSP-CI73T isoforms (blue arrows). (D) Western blot of AT2 lysates from IER-SP-CI73T/I73TFlp–/– or IER-SP-CI73T/I73TFlp+/– mice 2 weeks after iTAM for LC3 and SQSTM1/p62. Dot plots of densitometry for LC3 and p62 normalized to β-actin. *P < 0.05 versus control by 2-tailed t test. (E) Kaplan-Meier analysis for control IER-SP-CI73T/I73TFlp–/– mice treated with 300 mg/kg iTAM and IER-SP-CI73T/I73TFlp+/– groups treated with 200, 300, or 400 mg/kg iTAM (n = 11–33 / group). Mean survival using death or body weight <75% on 2 consecutive days as end points is shown. P < 0.05 for TAM IER-SP-CI73T/I73TFlp+/– at each iTAM dosage group (200, 300, or 400 mg/kg) versus TAM IER-SP-CI73T/I73TFlp–/– group using log-rank testing. (F) Survival of 8- to 12-week-old male (n =26) and female (n = 29) IER-SP-CI73T/I73TFlp+/– mice treated with 250–300 mg/kg iTAM. *P < 0.05 males versus females. (G) Representative H&E histology from surviving control and IER-SP-CI73T/I73TFlp+/– mice 14 days after 300 mg/kg iTAM. Scale bar: 300 μm. (H) BALF protein content in non-inducible IER-SP-CI73T/I73TFlp–/– or inducible IER-SP-CI73T/I73TFlp+/– mice after iTAM. Data from all time points for the non-inducible control group (gray dots) were combined. *P < 0.05 vs. IER-SP-CI73T/I73TFlp–/– by 1-way ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts